The target audience for Biocogniv consists primarily of hospitals, emergency rooms, and acute care facilities. This includes frontline healthcare providers, such as physicians, nurses, and lab technicians, who need tools to quickly and accurately diagnose and predict acute conditions like sepsis. The audience also includes hospital administrators and healthcare executives responsible for implementing new technologies and improving patient outcomes across their organizations. Additionally, the company appears to target larger healthcare systems and academic medical centers, as evidenced by their partnerships with UTMB and the validation studies conducted within a 1,000-bed system. Vituity is also mentioned as a partner, which employs thousands of frontline providers and staffs hundreds of hospitals. This suggests that Biocogniv is also interested in collaborating with large medical groups to implement their AI diagnostics.